Navigation Links
Halozyme Reports First Quarter 2012 Financial Results
Date:5/7/2012

rovide a corporate overview.

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Halozyme Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the EPO's anticipated issuance of a final written decision regarding our European patent for rHuPH20, Roche's anticipated filing of the Line Extension Application of subcutaneous MabThera® (rituxumab with rHuPH20) to the European Medicines Agency this year, our anticipated cash burn for 2012  and potential benefits and attributes of our product candidates. These statements involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
2. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
3. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
4. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
5. Halozyme Announces Proposed Public Offering of Common Stock
6. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
8. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
9. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
10. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
11. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Today the U.S. Food ... Bexsero® for the prevention of serogroup B meningococcal ... and Pfizer,s vaccine Trumenba®, which received FDA approval in ... this devastating disease. "I have heard ...
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... Cord Blood America, Inc . ( http://www.cordblood-america.com ) (OTC ... stem cell preservation company focused on bringing the ... internationally, announced today a Special Meeting of its shareholders on ... reverse stock split of one share for each 500 outstanding ...
... Calif., Feb. 10, 2011 PRO-DEX, INC. (Nasdaq: ... quarter and six months ended December 31, 2010. ... 8% to $6.2 million from $5.7 million for the corresponding ... the Company,s medical device products to its largest customer, and ...
Cached Medicine Technology:Cord Blood America Announces Special Shareholder Meeting 2Cord Blood America Announces Special Shareholder Meeting 3Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 2Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 3Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 4Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 5Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 6Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 7
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... TripAdvisor as the number one best large hotel for families ... world for their annual Travelers’ Choice Awards. , TripAdvisor ... website is home to millions of unbiased and honest traveler ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many ... it on Facebook, Twitter, and Pinterest. The fans will have ... a lottery every week. , Moreover, the company has extended ... Angelweddingdress homepage for more information. , Angelweddingdress ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... health, social skills in the process, experts say , FRIDAY, ... mean days spent at the beach or lake, afternoon bike ... is more likely to be lived in the not-so-great indoors, ... "human" contact. , The indoor child phenomenon concerns health experts ...
... A twice weekly hip strengthening regimen performed for six ... some cases eliminating -- knee pain referred to as ... study by Tracy Dierks, assistant professor in the Department ... based on the theory that stronger hips would correct ...
... ... better ROI , ... Rochester, NY and Piscataway NJ (PRWEB) June 4, 2010 -- UniteU Technologies, Inc., a ... optimizing solutions for online stores, are announcing the availability of Filtered Navigation Search Express ...
... Theurer Cancer Center at Hackensack University Medical Center announced ... the American Society of Clinical Oncology (ASCO) annual meeting ... Research highlights include a comparison of first-line treatments for ... of a new genetically engineered cancer therapy, and the ...
... Blood Institute (NHLBI) has stopped a clinical trial evaluating a ... children with sickle cell anemia and iron overload because of ... than the existing treatment. The 26-site trial, Stroke ... between the ages of 5 and 18 who had already ...
... role in the aging process appears to play a role ... according to researchers from the Center for Stem Cell Biology ... Jefferson University. In the study, published online in ... protein interaction that controls the silencing of Oct4, a key ...
Cached Medicine News:Health News:Move Childhood Back Outdoors This Summer 2Health News:Move Childhood Back Outdoors This Summer 3Health News:Hip exercises found effective at reducing, eliminating common knee pain in runners 2Health News:UniteU and Celebros Launch Dynamic Cross-Sell and New Version of Filtered Navigation Search 2Health News:UniteU and Celebros Launch Dynamic Cross-Sell and New Version of Filtered Navigation Search 3Health News:John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting 2Health News:John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting 3Health News:John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting 4Health News:Stroke prevention study in children with sickle cell anemia, iron overload stopped early 2Health News:Stroke prevention study in children with sickle cell anemia, iron overload stopped early 3Health News:Gene related to aging plays role in stem cell differentiation 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: